Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00041496
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date November 2001
Completion date December 2003

See also
  Status Clinical Trial Phase
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Terminated NCT00437242 - Odiparcil QT Definitive Study Phase 1
Completed NCT00402363 - Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation Phase 3
Completed NCT00240643 - Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke Phase 2
Not yet recruiting NCT06200311 - Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men N/A
Withdrawn NCT03401931 - Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers
Completed NCT04537507 - Atrial Fibrillation and Non-obstructive Coronary Lesions
Completed NCT04761315 - Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Registry)
Completed NCT00911300 - Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm Phase 2